NTRA Natera, Inc.
Natera, Inc. (NTRA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $5.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan 14 fills | Director | Sell 10b5-1 | 1,500 | $319.30 | $478.9K | 8,210 −15.4% of holding | |
| Sheena Jonathan 19 fills | Director | Sell 10b5-1 | 3,150 | $316.00 | $995.4K | 217,597 −1.4% of holding | |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 470 | $391.49 | $184.0K | 45,779 −1% of holding | |
| Chapman Steven Leonard 3 fills | CEO AND PRESIDENT | Sell 10b5-1 | 3,801 | $411.80 | $1.6M | 91,211 −4% of holding | |
| Moshkevich Solomon 12 fills | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 3,419 | $409.77 | $1.4M | 104,733 −3.2% of holding | |
| Rabinowitz Matthew 2 fills | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 748 | $400.02 | $299.2K | 2,117,659 −0% of holding | |
| RABINOWITZ DANIEL 2 fills | SEC. AND CHIEF LEGAL OFFICER | Sell 10b5-1 | 341 | $400.05 | $136.4K | 168,214 −0.2% of holding | |
| Brophy Michael Burkes 2 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 325 | $399.99 | $130.0K | 46,566 −0.7% of holding | |
| Fesko John 2 fills | PRESIDENT, CHIEF BUS. OFFICER | Sell 10b5-1 | 302 | $400.01 | $120.8K | 195,571 −0.2% of holding | |
| Sheena Jonathan 2 fills | Director | Sell 10b5-1 | 112 | $399.97 | $44.8K | 217,683 −0.1% of holding | |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 1,906 | $425.55 | $811.1K | 46,574 −3.9% of holding | |
| Chapman Steven Leonard | CEO AND PRESIDENT | Sell 10b5-1 | 3,430 | $426.34 | $1.5M | 91,232 −3.6% of holding | |
| Brophy Michael Burkes 3 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 2,376 | $426.40 | $1.0M | 49,658 −4.6% of holding | |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 1,162 | $426.34 | $495.4K | 104,742 −1.1% of holding | |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell 10b5-1 | 968 | $426.34 | $412.7K | 168,221 −0.6% of holding | |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell 10b5-1 | 898 | $426.34 | $382.9K | 195,578 −0.5% of holding | |
| Sheena Jonathan | Director | Sell 10b5-1 | 187 | $426.34 | $79.7K | 217,686 −0.1% of holding | |
| Chapman Steven Leonard | CEO AND PRESIDENT | Sell 10b5-1 | 2,264 | $406.00 | $919.2K | 94,662 −2.3% of holding | |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 1,718 | $406.00 | $697.5K | 2,117,676 −0.1% of holding | |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 1,010 | $406.00 | $410.1K | 105,904 −0.9% of holding | |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sell 10b5-1 | 884 | $406.00 | $358.9K | 169,189 −0.5% of holding | |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell 10b5-1 | 781 | $406.00 | $317.1K | 196,476 −0.4% of holding | |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 781 | $406.00 | $317.1K | 50,856 −1.5% of holding | |
| Sheena Jonathan | Director | Sell 10b5-1 | 291 | $406.00 | $118.1K | 217,873 −0.1% of holding | |
| Sheena Jonathan 8 fills | Director | Sell 10b5-1 | 3,150 | $410.55 | $1.3M | 221,114 −1.4% of holding | |
| Sheena Jonathan 12 fills | Director | Sell 10b5-1 | 1,500 | $402.47 | $603.7K | 8,858 −14.5% of holding | |
| Rabinowitz Matthew 19 fills | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 50,000 | $402.64 | $20.1M | 2,169,108 −2.3% of holding | |
| Moshkevich Solomon 3 fills | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 3,000 | $414.22 | $1.2M | 109,714 −2.7% of holding | |
| Chapman Steven Leonard | CEO AND PRESIDENT | Sell 10b5-1 | 1,273 | $413.31 | $526.1K | 96,926 −1.3% of holding | |
| Sheena Jonathan 12 fills | Director | Sell 10b5-1 | 18,064 | $388.01 | $7.0M | 17,642 −50.6% of holding | |
| Sheena Jonathan 6 fills | Director | Sell 10b5-1 | 3,150 | $354.19 | $1.1M | 224,264 −1.4% of holding | |
| Rabinowitz Matthew 14 fills | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 52,000 | $347.29 | $18.1M | 2,173,913 −2.3% of holding | |
| Sheena Jonathan | Director | Sell 10b5-1 | 6,000 | $350.07 | $2.1M | 224,464 −2.6% of holding | |
| Rabinowitz Matthew 15 fills | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 50,000 | $334.76 | $16.7M | 2,223,857 −2.2% of holding | |
| Rabinowitz Matthew 6 fills | EXECUTIVE CHAIRMAN | Sell 10b5-1 | 50,000 | $327.97 | $16.4M | 2,274,594 −2.2% of holding | |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 15,160 | $326.89 | $5.0M | 110,859 −12% of holding | |
| Moshkevich Solomon 3 fills | PRESIDENT, CLINICALDIAGNOSTICS | Sell 10b5-1 | 3,000 | $320.73 | $962.2K | 128,019 −2.3% of holding | |
| Chapman Steven Leonard | CEO AND PRESIDENT | Sell 10b5-1 | 1,698 | $320.99 | $545.0K | 98,199 −1.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.